Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in ICI-refractory malignancies
NCT05273255Completed
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic fecal microbiota in solid tumor. Primary endpoint: Change in the intestinal microbiome community at 24 weeks. Started Mar 2022; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05273255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273255.